BlackRock, Inc. Reports 4.9% Ownership in ARRIVENT BIOPHARMA INC

BlackRock, Inc. has filed a Schedule 13G/A amendment with the SEC, reporting a 4.9% ownership in ARRIVENT BIOPHARMA INC. The filing indicates that BlackRock, Inc. beneficially owns 2,007,338 shares of the company's common stock. The shares are held in the ordinary course of business and not for the purpose of influencing the control of the issuer. The filing also notes that no single person's interest in the common stock exceeds five percent of the total outstanding shares. The amendment was signed by Spencer Fleming, Managing Director of BlackRock, Inc., on October 17, 2025.